Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions

Lead Participant: PHARMATICS LIMITED

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening
of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death among
young athletes. Comorbidities due to gene mutations include altered vascular control, and, caused by HCM, ischemia, stroke, dementia,
or psychological and social difficulties. Multiple causal mutations and variations in cellular processes lead to highly diverse phenotypes
and disease progression. However, HCM is still diagnosed as one single disease, leading to suboptimal care. SMASH-HCM will develop
a digital-twin platform to dramatically improve HCM stratification and disease management, both for clinicians and patients. Multilevel
and multiorgan dynamic biophysical and data-driven models are integrated in a three-level deep phenotyping approach designed for
fast uptake into the clinical workflow. SMASH-HCM unites 8 research partners, 3 hospitals, 3 SMEs, and a global health-technology
corporation in collaboration with patients to advance the state of the art in human digital-twins: including in-vitro tools, in-silico from
molecular to systemic level models, structured and unstructured data analysis, explainable artificial intelligence - all integrated into
a decision support solution for both healthcare professionals and patients. SMASH-HCM delivers new insights into HCM, improved
patient care and guidance, validated preclinical tools, and above all, a first HCM stratification and management strategy, validated in a
pilot clinical trial, and tested with end users. Thus providing a cost efficient and effective solution for this complex disease. SMASHHCM develops a strategy towards fast regulatory approval. In reaching its goals, SMASH-HCM serves as a basis for future digital-twin
platforms for other cardiac diseases integrating models and data from various scales and sources.

Lead Participant

Project Cost

Grant Offer

PHARMATICS LIMITED £789,772 £ 789,772
 

Participant

INNOVATE UK

Publications

10 25 50